Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper Sandler, with Dr. Diana Gallagher, head of clinical development for MS, immunology, and Alzheimer’s disease, discussing late-stage lupus programs and earlier-stage pipeline efforts. Lupus focus: unmet need and long-running investment Gallagher said Biogen’s prioritization of lupus reflects both the […]